Trials / Conditions / Stage IVA Ovarian Cancer AJCC v8

Stage IVA Ovarian Cancer AJCC v8

20 registered clinical trials studyying Stage IVA Ovarian Cancer AJCC v8 — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients W NCT03735589	Roswell Park Cancer Institute	Phase 1 / Phase 2
Recruiting	Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Tr NCT05415709	Ohio State University Comprehensive Cancer Center	EARLY_Phase 1
Recruiting	Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Pa NCT05092373	M.D. Anderson Cancer Center	Phase 1
Recruiting	IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801	M.D. Anderson Cancer Center	Phase 1
Withdrawn	Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer NCT04498520	Pamela Munster	Phase 1
Recruiting	PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorecta NCT04329494	City of Hope Medical Center	Phase 1
Recruiting	Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary NCT04575935	M.D. Anderson Cancer Center	Phase 3
Recruiting	Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer NCT04794322	Massachusetts General Hospital	—
Completed	Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes NCT04501913	City of Hope Medical Center	—
Suspended	Paclitaxel Therapeutic Drug Monitoring in Cancer Patients NCT03987555	Wake Forest University Health Sciences	—
Recruiting	Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers NCT03968406	M.D. Anderson Cancer Center	Phase 1
Completed	A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors NCT03784677	M.D. Anderson Cancer Center	Phase 1
Completed	Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study NCT03707574	National Cancer Institute (NCI)	—
Active Not Recruiting	Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cance NCT03943173	M.D. Anderson Cancer Center	EARLY_Phase 1
Completed	Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer NCT04067960	Mayo Clinic	EARLY_Phase 1
Active Not Recruiting	Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistan NCT03907527	Precigen, Inc	Phase 1
Terminated	Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer NCT03606486	University of Washington	N/A
Completed	Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With NCT03508570	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Insta NCT03428802	Rutgers, The State University of New Jersey	Phase 2
Active Not Recruiting	Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY NCT02650986	Roswell Park Cancer Institute	Phase 1 / Phase 2